On July 23-24, FDA’s Pharmacy Compounding Advisory Committee (PCAC) convened to discuss the inclusion of seven peptides on the 503A Bulks lists.
The committee ultimately voted in favor of adding six of those peptides to the list, while one failed to win their support.
SO NOW WHAT?!?! PSD’s Marketing Manager Christian Hahn breaks it down. Watch now >
Founded in 2021 with a specialty in controlled substances, bulk chemical sourcing, and over 50 years of collective industry experience, Pharma Source Direct, Inc. came together to fill a void in the wholesale marketplace with one simple goal – provide the pharmaceutical compounding community with an alternative to cookie cutter wholesalers by offering our customers a truly customized buying experience. Whether you operate a traditional 503a Compounding Pharmacy or a 503b Outsourcing Facility, Pharma Source Direct is here to help.
This post is related to:
